SCHEMBL4384443

SCHEMBL4384443

Cc1csc(-c2ccnc(Nc3ccc(Cl)cc3)n2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.70
CDK2 P24941 5/20 0.70
SRC P12931 4/20 0.70
ZAP70 P43403 4/20 0.70
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
ALDH1A1 P00352 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
RAB9A P51151 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PIK3CA P42336 2/20 0.53
PIK3CB P42338 2/20 0.53
PIK3CG P48736 2/20 0.53
PLK1 P53350 1/20 0.52
AKT1 P31749 1/20 0.51
KDR P35968 1/20 0.51
PTK2 Q05397 1/20 0.51
EIF2AK2 P19525 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386062 0.81 CYP1A1 (0.66) CDK2MEN1MAPTKMT2APIK3CA
SCHEMBL13924481 0.80 SYK (0.77) SYKCDK2SRCZAP70PIK3CA
SCHEMBL14378895 0.79 CDK2 (0.70) SYKCDK2SRCZAP70PIK3CA
SCHEMBL4396898 0.77 SYK (0.53) SYKCDK2SRCZAP70NPC1
SCHEMBL4390469 0.77 ALDH1A1 (0.62) SYKCDK2SRCZAP70MEN1
SCHEMBL6157084 0.74 CDK2 (1.00) CDK2PLK1
SCHEMBL4385796 0.73 CDK2 (0.58) SYKCDK2SRCZAP70MEN1
SCHEMBL4389627 0.73 CDK2 (0.58) SYKCDK2SRCZAP70MEN1
SCHEMBL14216091 0.73 SYK (0.74) SYKCDK2SRCZAP70
SCHEMBL7475248 0.73 PLK1 (0.58) SYKCDK2MEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 SYK 3919/4885CDK2 1186/4885SRC 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.